Trial Profile

Phase Ib/IIa study of AG017 in patients with celiac disease

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AG 017 (Primary)
Indications Coeliac disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Aug 2019 New trial record
19 Aug 2019 According to an ActoBio Therapeutics therapeutics media release, the U.S. Food and Drug Administration (FDA) has given its permission to an Investigational New Drug (IND) application for AG017 for the treatment of celiac disease and the company plans to enroll patient later this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com